SEQUENTIAL ANTITHYMOCYTE GLOBULIN & AMIFOSTINE FOR MDS

序贯抗胸腺细胞球蛋白

• 批准号: 6586818
• 负责人: JEANNE E ANDERSON
• 金额: $ 23.48万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-12-01 至 2002-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6586818
• 关键词: acute myelogenous leukemia; antileukemic agent; blood disorder chemotherapy; clinical research; clinical trials; combination chemotherapy; drug interactions; dyserythropoietic anemia; human subject; human therapy evaluation; pathologic process

The myelodysplastic syndrome is a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, progressive peripheral cytopenias, and a tendency to progress to acute myeloid leukemia. New therapeutic options in MDS which are still under investigation include amifostine and antithymocite globulin (ATG). Although both amifostine and ATG have shown effects as individual agents in improving cytopenias and, perhaps, marrow blast count, there have been many patients treated with these agents who had none or minimal response in one or more cell lines. The cause of cytopenias and progression to AML is likely multifactorial. This study hypothesizes that treatment with the combination of the two agents -- each of which has a different mechanism of action -- may be synergistic in improving peripheral counts and reducing disease progression.

骨髓增生异常综合征是一组异质性克隆性造血系统疾病，其特征是无效造血，进行性外周血细胞减少，并有进展为急性髓性白血病的趋势。 仍在研究中的MDS的新治疗选择包括氨磷汀和抗胸腺嘧啶球蛋白（ATG）。虽然氨磷汀和ATG作为单独的药物在改善血细胞减少症和骨髓原始细胞计数方面都显示出效果，但已经有许多用这些药物治疗的患者在一种或多种细胞系中没有反应或反应极小。 血细胞减少和进展为AML的原因可能是多因素的。 这项研究假设，两种药物联合治疗-每种药物都有不同的作用机制-可能在改善外周计数和减少疾病进展方面具有协同作用。